Last reviewed · How we verify
Dexamethasone 3 mg
Dexamethasone 3 mg is a Small molecule drug developed by Centre Hospitalier Universitaire Vaudois. It is currently FDA-approved. Also known as: Corticosteroid.
Dexamethasone 3 mg, marketed by Centre Hospitalier Universitaire Vaudois, holds a position in the therapeutic landscape with a key composition patent expiring in 2028. The drug's primary strength lies in its well-established mechanism and broad clinical use, which supports its market presence. The primary risk is the potential increase in competition post-patent expiry in 2028.
At a glance
| Generic name | Dexamethasone 3 mg |
|---|---|
| Also known as | Corticosteroid |
| Sponsor | Centre Hospitalier Universitaire Vaudois |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Novel Combination Therapy in the Treatment of Relapsed and Refractory Aggressive B-Cell Lymphoma (PHASE2)
- A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011) (PHASE3)
- A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032) (PHASE3)
- Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors (MK-2870-009) (PHASE3)
- A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103) (PHASE3)
- A Treatment Study Protocol for Participants 0-45 Years With Acute Lymphoblastic Leukaemia (PHASE3)
- Management of Pain in Lumbar Arthrodesis (PHASE4)
- Epunamin Combined With DECP for Relapsed/Refractory Multiple Myeloma
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Dexamethasone 3 mg CI brief — competitive landscape report
- Dexamethasone 3 mg updates RSS · CI watch RSS
- Centre Hospitalier Universitaire Vaudois portfolio CI
Frequently asked questions about Dexamethasone 3 mg
What is Dexamethasone 3 mg?
Who makes Dexamethasone 3 mg?
Is Dexamethasone 3 mg also known as anything else?
What development phase is Dexamethasone 3 mg in?
Related
- Manufacturer: Centre Hospitalier Universitaire Vaudois — full pipeline
- Also known as: Corticosteroid
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing